Glasgow, UK, 21 September 2021 – Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the appointment of Joshua T. Brumm as its new Independent Chairman, succeeding Satish Jindal. Amphista’s CEO Dr Nicola Thompson said, “On behalf of the Amphista team I am thrilled to welcome someone of Josh’s calibre […]
This author has yet to write their bio.
Meanwhile lets just say that we are proud ginealach contributed a whooping 21 entries.
Bio21 14 June 2021 – 18 June 2021
Annual Drug Design and Medicinal Chemistry Congress, London 01 June 2021 – 02 June 2021
BioEquity Europe Digital 17 May 2021 – 19 May 2021
BIO-Europe Spring 22 March 2021 – 25 March 2021
Targeted Protein Degradation Europe Summit 17 March 2021 – 18 March 2021
This article was sourced from Endpoints. Since heading up GlaxoSmithKline’s protein degradation unit in 2012, Ian Churcher has witnessed a rapid explosion of interest in the idea of leveraging the body’s garbage disposal system to eliminate problematic proteins. Huge amounts of money are flowing in from biotech VCs and Big Pharma players, bankrolling a huge […]
Financing includes leading life-science investors Gilde Healthcare, Forbion, Novartis Venture Fund and Eli Lilly and Company Glasgow, UK, 17 March 2021 – Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the closing of a $53 million (£38 million) Series B financing round. The round was co-led by Forbion and […]
TITLE: Director of Chemistry LOCATION: tbd SALARY: Competitive salary and benefits package, relative to qualifications and experience POSITION SUMMARY Amphista Therapeutics is a fast-growing biotech and the leading Europe-based Targeted Protein Degradation (TPD) company. Initially founded from the laboratory of Professor Alessio Ciulli (University of Dundee) our team comprises both academic and drug discovery pioneers of the TPD […]
North American Protein Degradation Congress 16 Feb 2021 – 24 Feb 2021